News Sentiment

VRAX sentiment intelligence

Virax Biolabs Group Limited Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.08 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+30.4% over one week, -11.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

VRAX SEC Filings - Virax Biolabs Group Ltd 10-K, 10-Q, 8-K Forms

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction 30.4% Price confirming higher
Trend fit Trend inactive -11.3% over four weeks
Fair value -87.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 31
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 9
TipRanks 5
PR Newswire 4
Sahm 4
Quiver Quantitative 4
The Globe and Mail 4
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 9
Deals and strategy 3
Macro sensitivity 3
Balance sheet 2
Regulatory and legal 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TipRanks Direct company coverage

Virax Biolabs Raises $3.3 Million via Exercise of Investment Options and Issues New Warrants

Virax Biolabs Group Ltd. (VRAX) raised approximately $3.3 million by allowing an investor to exercise preferred investment options for 548,000 shares at a reduced price of $6.00 per share. In exchange for this immediate cash infusion and price reduction, the company will issue ne

Tone
Neutral 50/100
Event
Balance sheet
Published
10 Jul 2026 23:11
Source
TipRanks
TipRanks Direct company coverage

Virax Biolabs Strikes Exclusive Southeast Asia Supply Deal for ImmuneSelect with Fosun Diagnostics

Virax Biolabs' UK subsidiary has signed an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect products, granting access to six Southeast Asian markets. This deal allows for immediate purchase-order-driven sales and phased expansion, wi

Tone
Positive 74/100
Event
Deals and strategy
Published
10 Jul 2026 12:11
Source
TipRanks
Sahm Direct company coverage

Why Did Virax Biolabs Stock Triple In One Session?

Virax Biolabs Group Ltd. (NASDAQ: VRAX) saw its stock price triple after signing a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. This agreement expands Virax Biolabs' commercial footprint into six Southeast Asian markets and i

Tone
Positive 82/100
Event
Macro sensitivity
Published
09 Jul 2026 22:39
Source
Sahm
Quiver Quantitative Direct company coverage

Virax Biolabs Jumps on Fosun Diagnostics Supply Agreement

Virax Biolabs Group Limited (VRAX) stock surged 234.6% after announcing an exclusive multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line. The deal is expected to create immediate revenue potential in six Southeast Asian markets. The

Tone
Positive 75/100
Event
Earnings
Published
09 Jul 2026 15:50
Source
Quiver Quantitative
The Globe and Mail Direct company coverage

Virax Biolabs Approves 1-for-25 Share Consolidation to Maintain Nasdaq Listing

Virax Biolabs Group Ltd. (VRAX) has approved a 1-for-25 share consolidation to be effective on June 26, 2026. This move, previously approved by shareholders, aims to raise the company's share price to meet Nasdaq's minimum $1 bid-price requirement and prevent delisting. The conso

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:42
Source
The Globe and Mail
TipRanks Direct company coverage

Virax Biolabs Shareholders Approve Reverse Split and Amended Charter at June 12 Meeting

Virax Biolabs (VRAX) shareholders approved a reverse share consolidation of 10-to-1 to 30-to-1 and adopted a new memorandum and articles of association at a reconvened extraordinary meeting on June 12, 2026. This decision, made with only 3.65% of voting shares present due to adjo

Tone
Neutral 50/100
Event
Market update
Published
12 Jun 2026 13:38
Source
TipRanks
TipRanks Direct company coverage

Virax Biolabs Reports Strong Early Data for Long COVID Test and Prepares Larger Validation Study

Virax Biolabs reported strong early pilot data for its ViraxImmune blood-based test for Long COVID and related post-acute infection syndromes, showing high specificity and positive predictive value. The company plans a larger 300-patient validation study starting in Q4 2026, with

Tone
Positive 77/100
Event
Market update
Published
26 May 2026 11:39
Source
TipRanks
The Globe and Mail Direct company coverage

Virax Biolabs Calls June 5 EGM to Approve Reverse Share Split and Charter Amendments

Virax Biolabs Group Ltd. has called an Extraordinary General Meeting (EGM) for June 5, 2026, to vote on a proposed reverse share consolidation, charter amendments, and potential adjournment. The board unanimously recommends approval of these proposals, which aim to restructure th

Tone
Negative 39/100
Event
Regulatory and legal
Published
25 May 2026 04:11
Source
The Globe and Mail
Bez Kabli Direct company coverage

Virax Biolabs Stock Faces a Make-or-Break Nasdaq Vote After a Wild Week

Virax Biolabs (NASDAQ: VRAX) faces a critical Nasdaq vote on June 5 regarding a reverse share consolidation, vital for maintaining its listing as it needs to regain compliance with the exchange's $1 minimum bid rule by July 11. Despite a recent surge, the stock closed Friday at 2

Tone
Negative 32/100
Event
Market update
Published
24 May 2026 18:04
Source
Bez Kabli
Stock Titan Direct company coverage

Virax Biolabs (NASDAQ: VRAX) seeks 10–30 for 1 reverse split to meet Nasdaq bid rule

Virax Biolabs (NASDAQ: VRAX) is calling an extraordinary general meeting on June 5, 2026, to seek shareholder approval for a 10-for-1 to 30-for-1 reverse stock split. This action is necessary to regain compliance with Nasdaq's Minimum Bid Price Rule, which requires a share price

Tone
Negative 36/100
Event
Regulatory and legal
Published
23 May 2026 02:40
Source
Stock Titan
TechStock² Direct company coverage

Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open

Virax Biolabs (NASDAQ: VRAX) shares surged over 53% on Monday and continued to climb in premarket trading on Tuesday, driven by a recent ownership filing and a sponsored RedChip TV appearance. Despite the rally, the thinly traded diagnostics micro-cap remains a penny stock, tradi

Tone
Positive 64/100
Event
Market update
Published
19 May 2026 09:40
Source
TechStock²
Quiver Quantitative Direct company coverage

Virax Biolabs (VRAX) surges 177% as low-float momentum meets extreme short interest

Virax Biolabs (VRAX) stock surged 177.4% due to micro-cap momentum and short-squeeze dynamics, amplified by unusually high short interest relative to its public float. Recent short interest data indicated that shares sold short significantly exceeded the public float, and a Sched

Tone
Positive 77/100
Event
Market update
Published
18 May 2026 15:51
Source
Quiver Quantitative